Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

China Approves Zanubrutinib in Previously Untreated CLL/SLL and Waldenström Macroglobulinemia

May 8th 2023

China’s National Medical Products Administration has approved 2 supplemental new drug applications of zanubrutinib for use in treatment-naïve adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma and Waldenström macroglobulinemia.

Dr Wu on the Role of METTL3-Mediated m6A Modification in CLL Progression

April 26th 2023

Yiming Wu, PhD, discusses a study identifying METTL3-mediated N6-methyladenosine modification as a key translational regulator of splicing factors, and how this mechanism contributes to the progression of chronic lymphocytic leukemia.

Fixed-Duration Ibrutinib Plus Venetoclax Earns Approval in Canada for Previously Untreated CLL

March 28th 2023

Canada Health has approved the fixed-duration, all-oral combination of ibrutinib and venetoclax for the frontline treatment of adult patients with chronic lymphocytic leukemia, including those with 17p deletion.

Unmet Needs and Future Directions in Care in CLL

March 8th 2023

Closing out their discussion on novel treatment strategies in CLL, expert hematologist-oncologists address unmet needs and future directions in care.

Chronic Lymphocytic Leukemia: Emerging Therapeutic Targets

March 8th 2023

An in-depth review of novel therapeutic targets making their way into clinical trials for patients with chronic lymphocytic leukemia.

Dr. Mato on the Potential Use of Noncovalent BTK Inhibitors in CLL

March 2nd 2023

Anthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.

Optimal Sequencing of Therapy in Chronic Lymphocytic Leukemia

March 1st 2023

Following their discussion on novel therapeutic agents in chronic lymphocytic leukemia, panelists consider how these agents might be sequenced for optimal efficacy.

Evolving Role of Anti-CD20 Therapy in Chronic Lymphocytic Leukemia

March 1st 2023

Expert perspectives on the novel use of ant-CD20 therapy as first-line or combination treatment in chronic lymphocytic leukemia.

Davids Highlights Mounting Treatment Options in CLL

February 25th 2023

Patients with chronic lymphocytic leukemia, including those with difficult-to-treat disease classes such as double refractory, are quickly gaining more effective treatment options.

Acalabrutinib Tablet Formulation Approved in Europe for Chronic Lymphocytic Leukemia

February 22nd 2023

The European Commission has approved the tablet formulation of acalabrutinib for the treatment of adult patients with chronic lymphocytic leukemia.

Novel Strategies in Managing Patients With High-Risk Chronic Lymphocytic Leukemia

February 22nd 2023

Key opinion leaders provide their perspective on the optimal management of high-risk chronic lymphocytic leukemia with novel therapeutic agents.

Venetoclax + Second Generation BTKi Combination Therapy in R/R CLL

February 22nd 2023

Clinical trial updates evaluating the combination of venetoclax with second-generation BTK inhibitors acalabrutinib and zanabrutinib, respectively.

Clinical Trials in R/R CLL: Venetoclax + Ibrutinib Combination Therapy

February 15th 2023

Key updates from clinical trials evaluating the combination of venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Fixed Duration Venetoclax Therapy in Relapsed/Refractory CLL

February 15th 2023

Centering focus on the relapsed/refractory setting of CLL, panelists consider the use of fixed-duration venetoclax following updated clinical trial data in this setting.

Non-Covalent BTK Inhibitors in CLL: Updates from Clinical Trials With Pirtobrutinib

February 8th 2023

Expert perspectives on the role of non-covalent BTK inhibitors in managing patients diagnosed with chronic lymphocytic leukemia.

Chronic Lymphocytic Leukemia: Real World and QoL Evidence With BTKi

February 8th 2023

A panel of key opinion leaders elucidates real-world data with BTK inhibitors in CLL and considers the importance of patient-reported outcomes on quality of life.

Zanubrutinib Approval Underscores the Importance of Next-Generation BTK Inhibitors in CLL/SLL

February 7th 2023

Lamanna discussed key efficacy and safety data with zanubrutinib from the SEQUOIA and ALPINE trials, the advantages of zanubrutinib compared with previous therapeutic options, and how the approval of the agent will affect the use of next-generation BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma .

Ibrutinib/Venetoclax Shows Potential to Provide Durable Treatment-Free Remissions in CLL With MRD Negativity

February 3rd 2023

Ryan Jacobs, MD, highlighted the updated safety and efficacy results from the minimal residual disease cohort of the CAPTIVATE trial, discussed unanswered questions regarding minimal residual disease as a predictive vs prognostic tool in patients with chronic lymphocytic leukemia, and outlined areas that are ripe for further exploration.

Selecting the Appropriate BTKi in Chronic Lymphocytic Leukemia

February 1st 2023

Comprehensive perspectives on clinical factors that help to inform the selection of appropriate BTK inhibitor therapy for patients with chronic lymphocytic leukemia.

Head-to-Head Trials of BTKi in Chronic Lymphocytic Leukemia

February 1st 2023

Shared insight on and reactions to head-to-head comparison trials between novel BTK inhibitors in the setting of chronic lymphocytic leukemia.